Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Damian Pharma AG

Home Clinical Trial Sponsors and OrganizationsDamian Pharma AG

Damian Pharma AG

ACTIVE

Zug, SwitzerlandPrivate

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

5

2 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

3

60.0%

Phase 2

2

40.0%

Trial Status Distribution

Active, not recruiting

2

40.0%

Completed

3

60.0%

Clinical Trials

Trials sponsored by this organization (5)

Study in Patients with Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of the Aldosterone Synthase Inhibitor, DP13, over an 8-week Treatment Period

Active, not recruiting

Jan 202136 participants

Study in Patients with Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of the Aldosterone Synthase Inhibitor, DP13, over an 8-week Treatment Period

Active, not recruiting

Feb 202036 participants

DP13 - A Phase II Study in Patients With Primary Aldosteronism

Nov 201935 participants

DP13 SAD & MAD in Healthy Male Subjects

Mar 201748 participants

DP13 * A Phase II Study in Patients with Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of the Aldosterone Synthase Inhibitor, DP13, over an 8-week Treatment Period

15 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials5
Approvals
News

Back to Organizations